Spinraza denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Apply Step Therapy to Spinraza

Step-therapy requirements for Spinraza (nusinersen) typically arise when Aetna's policy requires documentation that another SMA-directed therapy — such as Evrysdi (risdiplam) or another covered agent — was tried first, or that the patient is clinically ineligible for the preferred agent. Alternatively, the policy may require that Spinraza be the first-line therapy only for specific patient populations, and the step-therapy denial signals that Aetna does not see the patient as fitting that population without additional documentation.

Given the severity and progressive nature of SMA, step-therapy denials in this disease area are frequently overturned on appeal — especially when the prescriber can document a clinical basis for the specific treatment choice.

## Federal Appeal Rights

• ACA §2719 external review: Non-grandfathered plans must offer external review after internal denial. The window is typically approximately four months from denial. External reviewers are not bound by Aetna's step-therapy protocol and apply an independent clinical standard.
• ERISA §503: Employer-plan members have the right to see the step-therapy protocol Aetna applied and to submit a rebuttal addressing each step.
• State step-therapy exception laws: Many states require insurers to grant step-therapy exceptions when a required therapy is clinically contraindicated, when equivalent therapy has already failed, or when the delay would cause irreversible harm. Check whether your state's law applies to your plan type.
• Expedited review: The progressive, irreversible nature of SMA motor neuron loss makes expedited appeal appropriate. Document urgency explicitly.

## Documentation to Gather

• Clinical rationale for Spinraza specifically: A detailed letter from the treating neuromuscular specialist explaining why Spinraza — rather than the step-therapy preferred agent — is the medically appropriate first choice for this patient, based on the patient's specific SMA type, mutation status, age, functional status, or other clinical factors.
• Contraindication or inadequacy of preferred step: If the step-therapy required agent is medically inappropriate, document the clinical reason with specificity.
• Prior SMA therapy history: If any SMA-directed therapy was previously tried, document dates, regimen, response, and reason for transition.
• Functional status and disease trajectory: Sequential chart documentation showing current functional status and the urgency of treatment.
• Diagnosis confirmation: Genetic testing results and specialist diagnosis notes.

## Criteria-Mapping Framework

Request Aetna's step-therapy policy for SMA treatments in writing. Address each required step:

| Aetna Step-Therapy Requirement | Patient-Specific Response | |---|---| | Trial of [preferred agent] required | [Agent] not appropriate because [clinical basis in specialist letter] | | Clinical exception criteria | Patient meets exception: [contraindication / prior failure / urgent need] | | Documentation of SMA type and severity | Genetic report + functional assessment attached |

The treating specialist's letter is the single most important element of this appeal. It should directly address Aetna's step-therapy logic and explain — in clinical terms — why this patient's treatment should begin with Spinraza.